1472pphase Ii Study of Carboplatin/etoposide plus Ly2510924, a Cxcr4 Peptide Antagonist, versus Carboplatin/etoposide in Patients with Extensive-stage Small Cell Lung Cancer (sclc).
نویسندگان
چکیده
D.R. Spigel1, R.W. Weaver2, M. McCleod3, O. Hamid4, J.R. Stille5, J. Polzer6, S. Roberson5, R. Salgia7 Lung Cancer Research Program, Sarah Cannon Research Institute, Nashville, TN, USA Medical Oncology, Florida Cancer Specialists, St. Petersburg, FL, USA Medical Oncology, Florida Cancer Specialists, Fort Myers, FL, USA Oncology, Eli Lilly and Company, Indianapolis, IN, USA Chorus, Eli Lilly and Company, Indianapolis, IN, USA Advanced Analytics Data Mining, Eli Lilly and Company, Indianapolis, IN, USA Dept. of Medicine, The University of Chicago Medical Centre, Chicago, IL, USA
منابع مشابه
A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer.
BACKGROUND Platinum plus etoposide is the standard therapy for extensive-stage small cell lung cancer (ES-SCLC) and is associated with significant myelosuppression. We hypothesized that the combination of carboplatin and nanoparticle albumin-bound paclitaxel (nab-paclitaxel) would be better tolerated. We investigated carboplatin with nab-paclitaxel on every-3-week and weekly schedules. METHOD...
متن کاملClinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide
Background. The effects of first-line chemotherapy on overall survival (OS) might be confounded by subsequent therapies in patients with small-cell lung cancer (SCLC). Therefore, by using individual-level data, we aimed to determine the relationships between progression-free survival (PFS) or postprogression survival (PPS) and OS after first-line chemotherapies in patients with extensive diseas...
متن کاملExperience with carboplatin and etoposide maintenance chemotherapy in patients with extensive stage small cell lung cancer.
PURPOSE To determine whether maintenance therapy with carboplatin and etoposide improves progression-free and overall survival in patients with extensive stage small cell lung cancer, compared to the standard four to six cycles of cisplatin and etoposide. METHODS Forty-two patient records (25 males and 17 females) were retrospectively reviewed in a single community practice. All patients were...
متن کاملCarboplatin in the Treatment of Small Cell Lung Cancer.
Small cell lung cancer (SCLC) will account for approximately 20%-25% of the 171,500 estimated new lung cancer cases in 1998. Combination cytotoxic therapies have yielded the best response rates in SCLC patients. Cisplatin in combination with etoposide is used routinely in the treatment of SCLC. Because of cisplatin's nonhematologic toxicities, carboplatin was developed and has far fewer nonhema...
متن کاملSmall cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent
The SCLC combination screen examined a 9-point concentration response of 180 third agents, alone and in combination with etoposide/carboplatin. The predominant effect of adding a third agent to etoposide/carboplatin was additivity. Less than additive effects occurred frequently in SCLC lines sensitive to etoposide/carboplatin. In SCLC lines with little or no response to etoposide/carboplatin, g...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Annals of oncology : official journal of the European Society for Medical Oncology
دوره 25 suppl_4 شماره
صفحات -
تاریخ انتشار 2014